Regeneron, Sanofi Blockbuster Dupixent Scores FDA Nod For Rare Sinus Condition

The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc. and Sanofi SA partnered Dupixent (dupilumab) for treating allergic fungal rhinosinusitis (AFRS).

• Regeneron Pharmaceuticals stock is facing resistance.

AFRS is a condition characterized by allergic hypersensitivity to fungi, which often leads to chronic sinus issues and surgery.

The approval covers Dupixent for patients aged six years and older with a history of sino-nasal surgery.

The approval is based on Phase 3 trial results that demonstrated Dupixent’s effectiveness in reducing nasal symptoms and the need for systemic corticosteroids or surgery compared to placebo.

Dupixent is now approved for nine distinct diseases driven by type 2 inflammation, including chronic rhinosinusitis with nasal polyps.

Technical Analysis

Currently, the stock is trading 5.2% below its 20-day simple moving average (SMA) and 8.4% below its 100-day SMA, indicating short-term weakness. Over the past 12 months, shares have increased approximately 64%, and they are currently positioned closer to their 52-week highs than lows, reflecting a generally positive long-term trend.

The RSI is at 50.00, which is considered neutral territory, suggesting the stock is neither overbought nor oversold. Meanwhile, MACD is at 0.10, below its signal line at 0.15, indicating bearish pressure on the stock.

The combination of neutral RSI and bearish MACD suggests mixed momentum, indicating that traders should watch for potential shifts in market sentiment.

• Key Resistance: $821
• Key Support: $750

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $819.70. Recent analyst moves include:

• Guggenheim: Buy (Raises target to $975 on Feb. 9)
• JP Morgan: Overweight (Raises target to $950 on Feb. 2)
• Oppenheimer: Outperform (Raises target to $865 on Feb. 2)

REGN Price Action: Regeneron Pharmaceuticals shares were down 0.77% at $781.01 at the time of publication on Tuesday, according to Benzinga Pro data.

Photo: Shutterstock AI Generator